PharmaMar SA: Revenue generating with marine-derived and novel MoA oncology products. 2019 total revenues of €85.8M. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Zepzelca (lurbinectedin), optimized analog of Yondelis, accelerated approval by FDA June 2020 for relapsed small cell lung cancer. Signed licensing agreement with Jazz Pharma for Lurbinectedin in the US - upfront payment of $200M, $100mm on approvaland up to $550M sales milestones. Jazz to launch Zepzelca in US July 2020.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed
Disease Space
Oncology
Finance
Profitable
Industry
Biotechnology
Listing
Public
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
Plaza del Descubridor Diego de Ordás 3
5th Floor
Madrid, 28003
Spain

Company Participants at Solebury Trout KOL Day

  • Pascal Besman, Chief Operating Officer (PharmaMar U.S.)

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.